{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:38:05Z","timestamp":1791999485128,"version":"4.4.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100008963","name":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04252-5","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T15:23:12Z","timestamp":1771341792000},"page":"1151-1164","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["SEOM\u2013TTCC clinical guideline for nasopharyngeal carcinoma (update 2025)"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5890-0149","authenticated-orcid":false,"given":"Antonio","family":"Rueda Dom\u00ednguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Cirauqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Garc\u00eda Casta\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Alvarez Cabellos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Carral Maseda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Castelo Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Iglesias Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Rubi\u00f3\u2011Casadevall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Arrazubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Mes\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"issue":"2","key":"4252_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.14639\/0392-100X-N2222","volume":"43","author":"G Cant\u00f9","year":"2023","unstructured":"Cant\u00f9 G. Nasopharyngeal carcinoma. A \u201cdifferent\u201d head and neck tumour. Part A: from histology to staging. Acta Otorhinolaryngol Ital. 2023;43(2):85\u201398. https:\/\/doi.org\/10.14639\/0392-100X-N2222.","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"4252_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394:64\u201380. https:\/\/doi.org\/10.1016\/S0140-6736(19)30956-0.","journal-title":"Lancet"},{"key":"4252_CR3","unstructured":"Cancer Today [Internet]. [cited 2025 Dec 11]. https:\/\/gco.iarc.who.int\/today\/en. Accessed 11 Dec 2025"},{"key":"4252_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANETWORKOPEN.2025.1895","author":"MB Alsavaf","year":"2025","unstructured":"Alsavaf MB, Marquardt M, Abouammo MD, Xu M, Elguindy A, Grecula J, et al. Patient characteristics and treatment outcomes of nasopharyngeal carcinoma in nonendemic regions. JAMA Netw Open. 2025. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2025.1895.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"4252_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.semcancer.2012.01.007","volume":"22","author":"A Hildesheim","year":"2012","unstructured":"Hildesheim A, Wang CP. Genetic predisposition factors and nasopharyngeal carcinoma risk: A review of epidemiological association studies, 2000-2011. Rosetta Stone for NPC: Genetics, viral infection, and other environmental factors. Semin Cancer Biol. 2012;22(2):107\u201316. https:\/\/doi.org\/10.1016\/j.semcancer.2012.01.007.","journal-title":"Semin Cancer Biol"},{"key":"4252_CR6","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2020.12.007","volume":"32","author":"P Bossi","year":"2021","unstructured":"Bossi P, Chan AT, Licitra L, Trama A, Orlandi E, Hui EP, et al. Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:452\u201365. https:\/\/doi.org\/10.1016\/j.annonc.2020.12.007.","journal-title":"Ann Oncol"},{"key":"4252_CR7","unstructured":"Sinha S, Winters R, Gajra A. Nasopharyngeal Cancer [Internet]. StatPearls Publishing; 2024 [cited 2025 Dec 11]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459256\/. Accessed 11 Dec 2025"},{"key":"4252_CR8","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.ejca.2015.07.043","volume":"51","author":"G Gatta","year":"2015","unstructured":"Gatta G, Botta L, S\u00e1nchez MJ, Anderson LA, Pierannunzio D, Licitra L, et al. Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study. Eur J Cancer. 2015;51:2130\u201343. https:\/\/doi.org\/10.1016\/j.ejca.2015.07.043.","journal-title":"Eur J Cancer"},{"key":"4252_CR9","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1007\/S12094-022-02814-X","volume":"24","author":"A Rueda Dom\u00ednguez","year":"2022","unstructured":"Rueda Dom\u00ednguez A, Cirauqui B, Garc\u00eda Casta\u00f1o A, Alvarez Cabellos R, Carral Maseda A, Castelo Fern\u00e1ndez B, et al. SEOM-TTCC clinical guideline in nasopharynx cancer (2021). Clin Transl Oncol. 2022;24:670\u201380. https:\/\/doi.org\/10.1007\/S12094-022-02814-X.","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"4252_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1086\/321805","volume":"33","author":"CA Dykewicz","year":"2001","unstructured":"Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33(2):139\u201344. https:\/\/doi.org\/10.1086\/321805.","journal-title":"Clin Infect Dis"},{"key":"4252_CR11","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1093\/annonc\/mdz106","volume":"30","author":"AD King","year":"2019","unstructured":"King AD, Woo JKS, Ai QY, Chan JSM, Lam WKJ, Tse IOL, et al. Complementary roles of MRI and endoscopic examination in the early detection of nasopharyngeal carcinoma. Ann Oncol. 2019;30:977\u201382. https:\/\/doi.org\/10.1093\/annonc\/mdz106.","journal-title":"Ann Oncol"},{"key":"4252_CR12","volume-title":"Head and Neck Tumoursvm","author":"AK El-Naggar","year":"2024","unstructured":"El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ. Head and Neck Tumoursvm. 5th ed. Lyon: IARC Publications; 2024.","edition":"5"},{"key":"4252_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/S12885-021-08311-8","author":"ET Beyene","year":"2021","unstructured":"Beyene ET, Ketema SG, Alebachew AN, Saleh MY, Gebremariam TA. Descriptive epidemiology of nasopharyngeal carcinoma at Tikur Anbessa Hospital, Ethiopia. BMC Cancer. 2021. https:\/\/doi.org\/10.1186\/S12885-021-08311-8.","journal-title":"BMC Cancer"},{"issue":"3","key":"4252_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/S12254-023-00903-3","volume":"16","author":"T Fuereder","year":"2023","unstructured":"Fuereder T. Nasopharyngeal carcinoma. memo Mag Eur Med Oncol. 2023;16(3):165\u20139. https:\/\/doi.org\/10.1007\/S12254-023-00903-3.","journal-title":"memo Mag Eur Med Oncol"},{"key":"4252_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/S00432-023-05547-8","author":"JS van Velsen","year":"2024","unstructured":"van Velsen JS, van der Vegt B, Plaat BEC, Langendijk JA, Epskamp-Kuijpers CCHJ, van Dijk BAC, et al. Nasopharyngeal carcinoma: nationwide trends in subtype-specific incidence and survival over 3 decades in a non-endemic area. J Cancer Res Clin Oncol. 2024. https:\/\/doi.org\/10.1007\/S00432-023-05547-8.","journal-title":"J Cancer Res Clin Oncol"},{"key":"4252_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/PATHOGENS9030226","author":"MAH Abusalah","year":"2020","unstructured":"Abusalah MAH, Gan SH, Al\u2010hatamleh MAI, Irekeola AA, Shueb RH, Yean CY. Recent advances in diagnostic approaches for Epstein-Barr virus. Pathogens. 2020. https:\/\/doi.org\/10.3390\/PATHOGENS9030226.","journal-title":"Pathogens"},{"issue":"1","key":"4252_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.4103\/NJMS.NJMS_14_17","volume":"9","author":"B Gupta","year":"2018","unstructured":"Gupta B, Bhattacharyya A, Singh A, Sah K, Gupta V. Basaloid squamous cell carcinoma - a rare and aggressive variant of squamous cell carcinoma: a case report and review of literature. Natl J Maxillofac Surg. 2018;9(1):64. https:\/\/doi.org\/10.4103\/NJMS.NJMS_14_17.","journal-title":"Natl J Maxillofac Surg"},{"key":"4252_CR18","unstructured":"Nasopharyngeal Carcinoma Treatment (PDQ\u00ae) - NCI [Internet]. [cited 2025 Dec 11]. https:\/\/www.cancer.gov\/types\/head-and-neck\/hp\/adult\/nasopharyngeal-treatment-pdq. Accessed 11 Dec 2025"},{"key":"4252_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/S13027-025-00661-3","author":"GZ Lu","year":"2025","unstructured":"Lu GZ, Huang YX, Guo LF, Yu YF, Lu ZZ, Lin Q, et al. Plasma Epstein-Barr virus DNA for the prediction of treatment response and disease progression in non-keratinizing differentiated nasopharyngeal carcinoma. Infect Agent Cancer. 2025. https:\/\/doi.org\/10.1186\/S13027-025-00661-3.","journal-title":"Infect Agent Cancer"},{"key":"4252_CR20","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMOA1701717","volume":"377","author":"KCA Chan","year":"2017","unstructured":"Chan KCA, Woo JKS, King A, Zee BCY, Lam WKJ, Chan SL, et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med. 2017;377:513\u201322. https:\/\/doi.org\/10.1056\/NEJMOA1701717.","journal-title":"N Engl J Med"},{"key":"4252_CR21","unstructured":"Lee AWM, Huang SH, Chua MLK, Lydiatt W, O\u2019Sullivan B, King AD, et al. AJCC Cancer Staging System: Nasopharynx \u2013 Version 9 [Internet]. American College of Surgeons; 2024 [cited 2025 Dec 11]. https:\/\/researchworks.creighton.edu\/esploro\/outputs\/book\/AJCC-Cancer-Staging-System-Nasopharynx\/991006149955102656. Accessed 11 Dec 2025"},{"key":"4252_CR22","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/J.1749-4486.2011.02405.X","volume":"36","author":"CR Chien","year":"2011","unstructured":"Chien CR, Lin HW, Yang CH, Yang SN, Wang YC, Kuo YC, et al. High case volume of radiation oncologists is associated with better survival of nasopharyngeal carcinoma patients treated with radiotherapy: a multifactorial cohort analysis. Clin Otolaryngol. 2011;36:558\u201365. https:\/\/doi.org\/10.1111\/J.1749-4486.2011.02405.X.","journal-title":"Clin Otolaryngol"},{"key":"4252_CR23","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.radonc.2014.02.003","volume":"110","author":"AWM Lee","year":"2014","unstructured":"Lee AWM, Ng WT, Chan LLK, Hung WM, Chan CCC, Sze HCK, et al. Evolution of treatment for nasopharyngeal cancer - success and setback in the intensity-modulated radiotherapy era. Radiother Oncol. 2014;110:377\u201384. https:\/\/doi.org\/10.1016\/j.radonc.2014.02.003.","journal-title":"Radiother Oncol"},{"issue":"2","key":"4252_CR24","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ijrobp.2017.09.038","volume":"100","author":"EJ Yoshida","year":"2018","unstructured":"Yoshida EJ, Luu M, David JM, Kim S, Mita A, Scher K, et al. Facility volume and survival in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2018;100(2):408\u201317. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.09.038.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"4252_CR25","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.oraloncology.2015.08.005","volume":"51","author":"B Zhang","year":"2015","unstructured":"Zhang B, Mo Z, Du W, Wang Y, Liu L, Wei Y. Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma: a systematic review and meta-analysis. Oral Oncol. 2015;51(11):1041\u20136. https:\/\/doi.org\/10.1016\/j.oraloncology.2015.08.005.","journal-title":"Oral Oncol"},{"issue":"1","key":"4252_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.radonc.2017.10.032","volume":"126","author":"AW Lee","year":"2018","unstructured":"Lee AW, Ng WT, Pan JJ, Poh SS, Ahn YC, AlHussain H, et al. International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. Radiother Oncol. 2018;126(1):25\u201336. https:\/\/doi.org\/10.1016\/j.radonc.2017.10.032.","journal-title":"Radiother Oncol"},{"issue":"5","key":"4252_CR27","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/S00066-017-1251-5","volume":"194","author":"C Lertbutsayanukul","year":"2018","unstructured":"Lertbutsayanukul C, Prayongrat A, Kannarunimit D, Chakkabat C, Netsawang B, Kitpanit S. A randomized phase III study between sequential versus simultaneous integrated boost intensity-modulated radiation therapy in nasopharyngeal carcinoma. Strahlenther Onkol. 2018;194(5):375\u201385. https:\/\/doi.org\/10.1007\/S00066-017-1251-5.","journal-title":"Strahlenther Onkol"},{"key":"4252_CR28","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1093\/JNCI\/DJR432","volume":"103","author":"QY Chen","year":"2011","unstructured":"Chen QY, Wen YF, Guo L, Liu H, Huang PY, Mo HY, et al. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst. 2011;103:1761\u201370. https:\/\/doi.org\/10.1093\/JNCI\/DJR432.","journal-title":"J Natl Cancer Inst"},{"key":"4252_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0194733","author":"F Liu","year":"2018","unstructured":"Liu F, Jin T, Liu L, Xiang Z, Yan R, Yang H. The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a systematic review and meta-analysis. PLoS ONE. 2018. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0194733.","journal-title":"PLoS ONE"},{"key":"4252_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2020.01314","author":"X Huang","year":"2020","unstructured":"Huang X, Chen X, Zhao C, Wang J, Wang K, Wang L, et al. Adding concurrent chemotherapy to intensity-modulated radiotherapy does not improve treatment outcomes for stage II nasopharyngeal carcinoma: a phase 2 multicenter clinical trial. Front Oncol. 2020. https:\/\/doi.org\/10.3389\/FONC.2020.01314.","journal-title":"Front Oncol"},{"key":"4252_CR31","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1470-2045(15)70126-9","volume":"16","author":"P Blanchard","year":"2015","unstructured":"Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015;16:645\u201355. https:\/\/doi.org\/10.1016\/S1470-2045(15)70126-9.","journal-title":"Lancet Oncol"},{"issue":"5","key":"4252_CR32","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1200\/JCO.2016.67.4119","volume":"35","author":"L Ribassin-Majed","year":"2017","unstructured":"Ribassin-Majed L, Marguet S, Lee AWM, Ng WT, Ma J, Chan ATC, et al. What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol. 2017;35(5):498\u2013505. https:\/\/doi.org\/10.1200\/JCO.2016.67.4119.","journal-title":"J Clin Oncol"},{"key":"4252_CR33","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/JNCI\/DJI084","volume":"97","author":"ATC Chan","year":"2005","unstructured":"Chan ATC, Leung SF, Ngan RKC, Teo PML, Lau WH, Kwan WH, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. JNCI J Natl Cancer Inst. 2005;97:536\u20139. https:\/\/doi.org\/10.1093\/JNCI\/DJI084.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"4252_CR34","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ejca.2007.03.022","volume":"43","author":"I Chitapanarux","year":"2007","unstructured":"Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, Sumitsawan Y, Tharavichitkul E, Sukthomya V, et al. Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial. Eur J Cancer [Internet]. 2007;43:1399\u2013406. https:\/\/doi.org\/10.1016\/j.ejca.2007.03.022.","journal-title":"Eur J Cancer [Internet]"},{"key":"4252_CR35","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/J.IJROBP.2010.03.024","volume":"80","author":"SZ Lai","year":"2011","unstructured":"Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu LZ, et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys. 2011;80:661\u20138. https:\/\/doi.org\/10.1016\/J.IJROBP.2010.03.024.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4252_CR36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejca.2016.12.039","volume":"75","author":"SM Cao","year":"2017","unstructured":"Cao SM, Yang Q, Guo L, Mai HQ, Mo HY, Cao KJ, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. Eur J Cancer. 2017;75:14\u201323. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.039.","journal-title":"Eur J Cancer"},{"issue":"1","key":"4252_CR37","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/IJC.32099","volume":"145","author":"WF Li","year":"2019","unstructured":"Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, et al. Concurrent chemoradiotherapy with\/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: long-term results of phase 3 randomized controlled trial. Int J Cancer. 2019;145(1):295\u2013305. https:\/\/doi.org\/10.1002\/IJC.32099.","journal-title":"Int J Cancer"},{"key":"4252_CR38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2019.07.007","volume":"119","author":"Q Yang","year":"2019","unstructured":"Yang Q, Cao SM, Guo L, Hua YJ, Huang PY, Zhang XL, et al. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Eur J Cancer. 2019;119:87\u201396. https:\/\/doi.org\/10.1016\/j.ejca.2019.07.007.","journal-title":"Eur J Cancer"},{"key":"4252_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103244","author":"A Bongiovanni","year":"2021","unstructured":"Bongiovanni A, Vagheggini A, Fausti V, Mercatali L, Calpona S, Di Menna G, et al. Induction chemotherapy plus concomitant chemoradiotherapy in nasopharyngeal carcinoma: an updated network meta-analysis. Crit Rev Oncol Hematol. 2021. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103244.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4252_CR40","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1158\/1078-0432.CCR-17-2656","volume":"24","author":"YP Chen","year":"2018","unstructured":"Chen YP, Tang LL, Yang Q, Poh SS, Hui EP, Chan ATC, et al. Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials. Clin Cancer Res. 2018;24:1824\u201333. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2656.","journal-title":"Clin Cancer Res"},{"key":"4252_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2021.626145","author":"HCW Choi","year":"2021","unstructured":"Choi HCW, Chan SK, Lam KO, Chan SY, Chau SC, Kwong DLW, et al. The most efficacious induction chemotherapy regimen for locoregionally advanced nasopharyngeal carcinoma: a network meta-analysis. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/FONC.2021.626145.","journal-title":"Front Oncol"},{"key":"4252_CR42","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1002\/ONCO.13520","volume":"26","author":"M Man\u00e9","year":"2021","unstructured":"Man\u00e9 M, Benkhaled S, Dragan T, Paesmans M, Beauvois S, Lalami Y, et al. Meta-analysis on induction chemotherapy in locally advanced nasopharyngeal carcinoma. Oncologist. 2021;26:e130-41. https:\/\/doi.org\/10.1002\/ONCO.13520.","journal-title":"Oncologist"},{"key":"4252_CR43","doi-asserted-by":"publisher","first-page":"6523","DOI":"10.1200\/JCO.2020.38.15_SUPPL.6523","volume":"38","author":"C Petit","year":"2020","unstructured":"Petit C, Lee AW, Carmel A, Ng WT, Ma J, Chan AT, et al. Network-meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): an update on 8,221 patients. J Clin Oncol. 2020;38:6523\u20136523. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_SUPPL.6523.","journal-title":"J Clin Oncol"},{"key":"4252_CR44","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017486","volume":"98","author":"BC Wang","year":"2019","unstructured":"Wang BC, Shi LL, Fu C, Zhou HX, Zhang ZJ, Ding Q, et al. A meta-analysis of cisplatin-based concurrent chemoradiotherapy with or without cetuximab for locoregionally advanced nasopharyngeal carcinoma. Medicine. 2019;98:e17486. https:\/\/doi.org\/10.1097\/MD.0000000000017486.","journal-title":"Medicine"},{"key":"4252_CR45","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMOA1905287","volume":"381","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Chen L, Hu G-Q, Zhang N, Zhu X-D, Yang K-Y, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med. 2019;381:1124\u201335. https:\/\/doi.org\/10.1056\/NEJMOA1905287.","journal-title":"N Engl J Med"},{"key":"4252_CR46","doi-asserted-by":"publisher","first-page":"4825","DOI":"10.7150\/THNO.21815","volume":"7","author":"R You","year":"2017","unstructured":"You R, Cao YS, Huang PY, Chen L, Yang Q, Liu YP, et al. The changing therapeutic role of chemo-radiotherapy for loco-regionally advanced nasopharyngeal carcinoma from two\/three-dimensional radiotherapy to intensity-modulated radiotherapy: a network meta-analysis. Theranostics. 2017;7:4825\u201335. https:\/\/doi.org\/10.7150\/THNO.21815.","journal-title":"Theranostics"},{"key":"4252_CR47","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANETWORKOPEN.2019.13619","volume":"2","author":"B Zhang","year":"2019","unstructured":"Zhang B, Li MM, Chen WH, Zhao JF, Chen WQ, Dong YH, et al. Association of chemoradiotherapy regimens and survival among patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. JAMA Netw Open. 2019;2:e1913619. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2019.13619.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"4252_CR48","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S1470-2045(11)70320-5","volume":"13","author":"L Chen","year":"2012","unstructured":"Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012;13(2):163\u201371. https:\/\/doi.org\/10.1016\/S1470-2045(11)70320-5.","journal-title":"Lancet Oncol"},{"key":"4252_CR49","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ejca.2017.01.002","volume":"75","author":"L Chen","year":"2017","unstructured":"Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, et al. Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase 3 multicentre randomised controlled trial. Eur J Cancer. 2017;75:150\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2017.01.002.","journal-title":"Eur J Cancer"},{"issue":"1","key":"4252_CR50","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/annonc\/mdu507","volume":"26","author":"YP Chen","year":"2015","unstructured":"Chen YP, Wang ZX, Chen L, Liu X, Tang LL, Mao YP, et al. A bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. Ann Oncol. 2015;26(1):205\u201311. https:\/\/doi.org\/10.1093\/annonc\/mdu507.","journal-title":"Ann Oncol"},{"key":"4252_CR51","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.ejca.2015.04.027","volume":"51","author":"M Yan","year":"2015","unstructured":"Yan M, Kumachev A, Siu LL, Chan KKW. Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: a bayesian network meta-analysis. Eur J Cancer. 2015;51:1570\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2015.04.027.","journal-title":"Eur J Cancer"},{"key":"4252_CR52","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1200\/JCO.2018.77.7847","volume":"36","author":"ATC Chan","year":"2018","unstructured":"Chan ATC, Hui EP, Ngan RKC, Tung SY, Cheng ACK, Ng WT, et al. Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial. J Clin Oncol. 2018;36:3091\u2013100. https:\/\/doi.org\/10.1200\/JCO.2018.77.7847.","journal-title":"J Clin Oncol"},{"key":"4252_CR53","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1200\/JCO.22.02764","volume":"41","author":"M Al-Sarraf","year":"2023","unstructured":"Al-Sarraf M, Leblanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 2023;41:1310\u20137. https:\/\/doi.org\/10.1200\/JCO.22.02764.","journal-title":"J Clin Oncol"},{"key":"4252_CR54","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(21)01123-5","volume":"398","author":"YP Chen","year":"2021","unstructured":"Chen YP, Liu X, Zhou Q, Yang KY, Jin F, Zhu XD, et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2021;398:303\u201313. https:\/\/doi.org\/10.1016\/S0140-6736(21)01123-5.","journal-title":"Lancet"},{"key":"4252_CR55","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1001\/JAMAONCOL.2022.4656","volume":"8","author":"J Miao","year":"2022","unstructured":"Miao J, Wang L, Tan SH, Li JG, Yi J, Ong EHW, et al. Adjuvant capecitabine following concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a randomized clinical trial. JAMA Oncol. 2022;8:1776\u201385. https:\/\/doi.org\/10.1001\/JAMAONCOL.2022.4656.","journal-title":"JAMA Oncol"},{"key":"4252_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.1953","volume":"36","author":"J Miao","year":"2025","unstructured":"Miao J, Xiang C, Liu C, Guo Y, Guo X, Xiang Y-Q, et al. 1321O concurrent chemoradiotherapy with\/without adjuvant capecitabine in locoregionally advanced nasopharyngeal carcinoma: a randomized controlled phase III trial. Ann Oncol. 2025;36:S825\u20136. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.1953.","journal-title":"Ann Oncol"},{"key":"4252_CR57","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1002\/HED.70034","volume":"47","author":"W Ben Kridis","year":"2025","unstructured":"Ben Kridis W, Khanfir A. Efficacy and safety of adjuvant capecitabine in locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of phase III randomized trials with subgroup analysis by neoadjuvant chemotherapy. Head Neck. 2025;47:3193\u2013200. https:\/\/doi.org\/10.1002\/HED.70034.","journal-title":"Head Neck"},{"key":"4252_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.101890","author":"AWM Lee","year":"2019","unstructured":"Lee AWM, Ng WT, Chan JYW, Corry J, M\u00e4kitie A, Mendenhall WM, et al. Management of locally recurrent nasopharyngeal carcinoma. Cancer Treat Rev. 2019. https:\/\/doi.org\/10.1016\/j.ctrv.2019.101890.","journal-title":"Cancer Treat Rev"},{"key":"4252_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2020.555862","author":"Q Liu","year":"2021","unstructured":"Liu Q, Sun X, Li H, Zhou J, Gu Y, Zhao W, et al. Types of transnasal endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma: Shanghai EENT hospital experience. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/FONC.2020.555862.","journal-title":"Front Oncol"},{"key":"4252_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/CANCERS12123510","volume":"12","author":"M Svajdova","year":"2020","unstructured":"Svajdova M, Sicak M, Dubinsky P, Slavik M, Slampa P, Kazda T. Recurrent nasopharyngeal cancer: critical review of local treatment options including recommendations during the COVID-19 pandemic. Cancers (Basel). 2020;12:1\u201319. https:\/\/doi.org\/10.3390\/CANCERS12123510.","journal-title":"Cancers (Basel)"},{"key":"4252_CR61","doi-asserted-by":"publisher","DOI":"10.1007\/S11912-020-00949-0","author":"CY Hao","year":"2020","unstructured":"Hao CY, Hao SP. The management of rNPC: salvage surgery vs. re-irradiation. Curr Oncol Rep. 2020. https:\/\/doi.org\/10.1007\/S11912-020-00949-0.","journal-title":"Curr Oncol Rep"},{"key":"4252_CR62","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1016\/j.ejca.2015.05.014","volume":"51","author":"R You","year":"2015","unstructured":"You R, Zou X, Wang SL, Jiang R, Tang LQ, Zhang WD, et al. New surgical staging system for patients with recurrent nasopharyngeal carcinoma based on the AJCC\/UICC rTNM classification system. Eur J Cancer. 2015;51:1771\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2015.05.014.","journal-title":"Eur J Cancer"},{"key":"4252_CR63","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1245\/S10434-014-3683-9","volume":"21","author":"S Na\u2019ara","year":"2014","unstructured":"Na\u2019ara S, Amit M, Billan S, Cohen JT, Gil Z. Outcome of patients undergoing salvage surgery for recurrent nasopharyngeal carcinoma: a meta-analysis. Ann Surg Oncol. 2014;21:3056\u201362. https:\/\/doi.org\/10.1245\/S10434-014-3683-9.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"4252_CR64","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/LARY.24193","volume":"124","author":"JYW Chan","year":"2014","unstructured":"Chan JYW, Wong STS. The role of plasma Epstein-Barr virus DNA in the management of recurrent nasopharyngeal carcinoma. Laryngoscope. 2014;124(1):126\u201330. https:\/\/doi.org\/10.1002\/LARY.24193.","journal-title":"Laryngoscope"},{"key":"4252_CR65","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S1470-2045(20)30673-2","volume":"22","author":"YP Liu","year":"2021","unstructured":"Liu YP, Wen YH, Tang J, Wei Y, You R, Zhu XL, et al. Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:381\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(20)30673-2.","journal-title":"Lancet Oncol"},{"key":"4252_CR66","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1200\/JCO.2017.75.5165","volume":"36","author":"YQ Li","year":"2018","unstructured":"Li YQ, Tian YM, Tan SH, Liu MZ, Kusumawidjaja G, Ong EHW, et al. Prognostic Model for Stratification of Radioresistant Nasopharynx Carcinoma to Curative Salvage Radiotherapy. J Clin Oncol. 2018;36:891\u20138. https:\/\/doi.org\/10.1200\/JCO.2017.75.5165.","journal-title":"J Clin Oncol"},{"key":"4252_CR67","doi-asserted-by":"publisher","DOI":"10.21037\/CCO.2016.03.19","author":"L Kong","year":"2016","unstructured":"Kong L, Lu JJ. Reirradiation of locally recurrent nasopharyngeal cancer: history, advances, and promises for the future. Chin Clin Oncol. 2016. https:\/\/doi.org\/10.21037\/CCO.2016.03.19.","journal-title":"Chin Clin Oncol"},{"issue":"5","key":"4252_CR68","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/CAC2.12159","volume":"41","author":"SS Poh","year":"2021","unstructured":"Poh SS, Soong YL, Sommat K, Lim CM, Fong KW, Tan TWK, et al. Retreatment in locally recurrent nasopharyngeal carcinoma: current status and perspectives. Cancer Commun (Lond). 2021;41(5):361\u201370. https:\/\/doi.org\/10.1002\/CAC2.12159.","journal-title":"Cancer Commun (Lond)"},{"issue":"11","key":"4252_CR69","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/S41571-021-00524-X","volume":"18","author":"KCW Wong","year":"2021","unstructured":"Wong KCW, Hui EP, Lo KW, Lam WKJ, Johnson D, Li L, et al. Nasopharyngeal carcinoma: an evolving paradigm. Nat Rev Clin Oncol. 2021;18(11):679\u201395. https:\/\/doi.org\/10.1038\/S41571-021-00524-X.","journal-title":"Nat Rev Clin Oncol"},{"key":"4252_CR70","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1001\/JAMAONCOL.2020.1808","volume":"6","author":"R You","year":"2020","unstructured":"You R, Liu YP, Huang PY, Zou X, Sun R, He YX, et al. Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemotherapy alone in de novo metastatic nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial. JAMA Oncol. 2020;6:1345\u201352. https:\/\/doi.org\/10.1001\/JAMAONCOL.2020.1808.","journal-title":"JAMA Oncol"},{"key":"4252_CR71","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","volume":"19","author":"W Fang","year":"2018","unstructured":"Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018;19:1338\u201350. https:\/\/doi.org\/10.1016\/S1470-2045(18)30495-9.","journal-title":"Lancet Oncol"},{"key":"4252_CR72","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","volume":"35","author":"C Hsu","year":"2017","unstructured":"Hsu C, Lee SH, Ejadi S, Even C, Cohen RB, Le Tourneau C, et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin Oncol. 2017;35:4050\u20136. https:\/\/doi.org\/10.1200\/JCO.2017.73.3675.","journal-title":"J Clin Oncol"},{"key":"4252_CR73","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1634\/THEONCOLOGIST.2019-0284","volume":"24","author":"Y Ma","year":"2019","unstructured":"Ma Y, Fang W, Zhang Y, Yang Y, Hong S, Zhao Y, et al. A phase I\/II open-label study of nivolumab in previously treated advanced or recurrent nasopharyngeal carcinoma and other solid tumors. Oncologist. 2019;24:891-e431. https:\/\/doi.org\/10.1634\/THEONCOLOGIST.2019-0284.","journal-title":"Oncologist"},{"key":"4252_CR74","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.annonc.2022.12.007","volume":"34","author":"ATC Chan","year":"2023","unstructured":"Chan ATC, Lee VHF, Hong RL, Ahn MJ, Chong WQ, Kim SB, et al. Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial. Ann Oncol. 2023;34:251\u201361. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.007.","journal-title":"Ann Oncol"},{"key":"4252_CR75","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393:2051\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(18)32487-5.","journal-title":"Lancet"},{"key":"4252_CR76","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.oraloncology.2015.10.010","volume":"52","author":"J Wei","year":"2016","unstructured":"Wei J, Pei S, Zhu X. Comparison of (18)F-FDG PET\/CT, MRI and SPECT in the diagnosis of local residual\/recurrent nasopharyngeal carcinoma: a meta-analysis. Oral Oncol. 2016;52:11\u20137. https:\/\/doi.org\/10.1016\/j.oraloncology.2015.10.010.","journal-title":"Oral Oncol"},{"key":"4252_CR77","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20190691","author":"H Peng","year":"2019","unstructured":"Peng H, Li Z, Long Y, Li J, Liu Z, Zhou R. Clinical value of a plasma Epstein-Barr virus DNA assay in the diagnosis of recurrent or metastatic nasopharyngeal carcinoma: a meta-analysis. 2019. Biosci Rep. https:\/\/doi.org\/10.1042\/BSR20190691."},{"key":"4252_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/S13014-016-0704-9","author":"A Kiang","year":"2016","unstructured":"Kiang A, Weinberg VK, Cheung KHN, Shugard E, Chen J, Quivey JM, et al. Long-term disease-specific and cognitive quality of life after intensity-modulated radiation therapy: a cross-sectional survey of nasopharyngeal carcinoma survivors. Radiat Oncol. 2016. https:\/\/doi.org\/10.1186\/S13014-016-0704-9.","journal-title":"Radiat Oncol"},{"issue":"1","key":"4252_CR79","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/BJC.2013.720","volume":"110","author":"L Zeng","year":"2014","unstructured":"Zeng L, Tian YM, Sun XM, Chen CY, Han F, Xiao WW, et al. Late toxicities after intensity-modulated radiotherapy for nasopharyngeal carcinoma: patient and treatment-related risk factors. Br J Cancer. 2014;110(1):49\u201354. https:\/\/doi.org\/10.1038\/BJC.2013.720.","journal-title":"Br J Cancer"},{"key":"4252_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-94","author":"J J\u00e9gu","year":"2014","unstructured":"J\u00e9gu J, Colonna M, Daubisse-Marliac L, Tr\u00e9tarre B, Ganry O, Guizard AV, et al. The effect of patient characteristics on second primary cancer risk in France. BMC Cancer. 2014. https:\/\/doi.org\/10.1186\/1471-2407-14-94.","journal-title":"BMC Cancer"},{"key":"4252_CR81","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/S12094-020-02470-Z","volume":"23","author":"J Rubi\u00f3-Casadevall","year":"2021","unstructured":"Rubi\u00f3-Casadevall J, Galceran J, Ameijide A, Puigdemont M, Llaurad\u00f3 L, Marruecos J, et al. Population-based risk assessment of second primary cancers following a first head and neck cancer: patterns of association and difficulties of its analysis. Clin Transl Oncol. 2021;23:788\u201398. https:\/\/doi.org\/10.1007\/S12094-020-02470-Z.","journal-title":"Clin Transl Oncol"},{"key":"4252_CR82","unstructured":"Curtis RE, Michal Freedman D, Ron E, G Ries LA, Hacker DG, Edwards BK, et al. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973\u20132000. 1973 [cited 2025 Dec 11]; http:\/\/seer.cancer.gov. Accessed 11 Dec 2025"},{"key":"4252_CR83","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.radonc.2015.04.024","volume":"115","author":"R You","year":"2015","unstructured":"You R, Zou X, Hua YJ, Han F, Li L, Zhao C, et al. Salvage endoscopic nasopharyngectomy is superior to intensity-modulated radiation therapy for local recurrence of selected T1-T3 nasopharyngeal carcinoma - a case-matched comparison. Radiother Oncol. 2015;115:399\u2013406. https:\/\/doi.org\/10.1016\/j.radonc.2015.04.024.","journal-title":"Radiother Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04252-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04252-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04252-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:04:06Z","timestamp":1774415046000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04252-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":83,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4252"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04252-5","relation":{"references":[{"id-type":"doi","id":"10.1042\/BSR20190691","asserted-by":"subject"}]},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Antonio Rueda Dom\u00ednguez has received speaker fees and attended advisory boards for BMS, MSD, Merck, Roche, and Takeda; and has attended an advisory board for Gilead. Beatriz Cirauqui has received speaker fees and attended an advisory board for BMS, MSD, Merck, and Leo Pharma; and has received other fees from BMS, MSD, and Merck. Leticia Iglesias Rey has received speaker fees from Novartis, Roche, and Pfizer; and has received speaker fees and attended an advisory board for BMS. Virginia Arrazubi has attended an advisory boards for BMS and MSD; has received speaker fees from Organon, Astellas, AstraZeneca, BiOne, MSD; and has received non-financial support from Merck. Ricard Mes\u00eda has received speaker fees and attended advisory boards for Merck and MSD; has attended an advisory boards for Bayer, Roche, Nanobiotix, and Seagen; and has received speaker fees from BMS. Almudena Garc\u00eda Casta\u00f1o, Ruth Alvarez Cabellos, Alberto Carral Maseda, Beatriz Castelo Fern\u00e1ndez, and Jordi Rubi\u00f3\u2011Casadevall have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable. The manuscript does not contain clinical studies or patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}}]}}